Patents Assigned to The J. David Gladstone Institutes
  • Publication number: 20190284254
    Abstract: This invention provides methods for promoting and/or restoring neurite outgrowth and neuronal regeneration by contacting an injured neuron with an inhibitor of low density lipoprotein receptor-related protein-1 (LRP-1).
    Type: Application
    Filed: June 22, 2016
    Publication date: September 19, 2019
    Applicant: The J. David Gladstone Institutes
    Inventors: Steven L. Gonias, Travis Stiles, Alban Gaultier, Wendy M. Campana, Katerina Akassoglou
  • Publication number: 20190248730
    Abstract: Aspects of the present disclosure include fatty acid ?-hydroxyester compounds (e.g., fatty acid esters of ?-hydroxybutyrate), fatty acid esters of butanediol, and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions having one or more fatty acid ?-hydroxyester compounds and/or one or more fatty acid esters of butanediol. Methods for treating a subject by administering one or more esters to the subject are also provided. Kits containing one or more of the subject esters are also described.
    Type: Application
    Filed: June 2, 2017
    Publication date: August 15, 2019
    Applicants: THE J. DAVID GLADSTONE INSTITUTES, ITHACA COLLEGE, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, ITHACA COLLEGE
    Inventors: Eric Verdin, Scott Michael Ulrich, John C. Newman
  • Patent number: 10363256
    Abstract: Methods for decreasing rod gene expression in a retina, methods for decreasing the protein products expressed by rod genes in a retina, methods for treating a disease or condition treatable by decreasing rod gene expression or their protein products in a retina, and methods for treating a retinal disease in a subject.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: July 30, 2019
    Assignees: University of Washington, The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Gladstone
    Inventors: Thomas A. Reh, Paul Nakamura, Sheng Ding
  • Patent number: 10351853
    Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus and/or reducing transcription of HIV integrated into the genome of an HIV-infected cell. The present disclosure provides compositions and methods for treating an immunodeficiency virus infection.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: July 16, 2019
    Assignee: The J. David Gladstone Institutes
    Inventors: Melanie Ott, Daniela Boehm
  • Patent number: 10280451
    Abstract: Methods, compositions, and kits are provided for quantification of genome editing.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: May 7, 2019
    Assignees: Bio-Rad Laboratories, Inc., J. David Gladstone Institutes
    Inventors: Jennifer Berman, Samantha Cooper, George Karlin-Neumann, Yuichiro Miyaoka, Bruce Conklin, Josh Shinoff
  • Patent number: 10247735
    Abstract: The present disclosure provides compositions for regulating glucose metabolism. The compositions provide for reduced levels of p75NTR and/or reduced binding of p75NTR to a GTPase such as Rab31 or Rab5. The compositions are useful in methods of regulating glucose metabolism, which methods are also provided.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: April 2, 2019
    Assignee: The J. David Gladstone Institutes
    Inventor: Katerina Akassoglou
  • Patent number: 10227565
    Abstract: Compositions and methods are described herein for inducing reprogramming of non-pluripotent cells across lineage and differentiation boundaries to generate endodermal progenitor cells and hepatocytes. Compositions and methods for expansion of endodermal progenitor cells without loss of phenotype are also described herein.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: March 12, 2019
    Assignees: The J. David Gladstone Institutes, The Regents of the University of California
    Inventors: Saiyong Zhu, Sheng Ding, Holger Willenbring, Milad Rezvani, Jack Harbell
  • Patent number: 10144915
    Abstract: Compositions and methods are described herein for chemically inducing cells that express a single pluripotency transcription factor to change their differentiation state and become cardiac cells, cardiac progenitor cells, cardiomyocytes, or a combination thereof.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: December 4, 2018
    Assignee: THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE
    Inventors: Haixia Wang, Sheng Ding
  • Patent number: 10106817
    Abstract: A recombinant expression vector comprising a nucleotide sequence encoding a herpesvirus transactivator, where the nucleotide sequence is operably linked to a herpesvirus control element is provided as are cell lines genetically modified to express a herpesvirus transactivator under the control of a herpesvirus control element. Also provided are methods of identifying agents that disrupt feedback regulation of a herpesvirus transcriptional control element by a herpesvirus transactivator.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: October 23, 2018
    Assignee: The J. David Gladstone Institutes
    Inventor: Leor S. Weinberger
  • Patent number: 10106818
    Abstract: The present disclosure provides for recombinant nucleic acids, and cells and virions comprising the recombinant nucleic acids, that can be used to identify, isolate, and/or purify cells latently infected with immunodeficiency virus. A subject recombinant nucleic acid includes (a) a first nucleotide sequence encoding a first reporter polypeptide that produces a first detectable signal, where the first nucleotide sequence is operably linked to an immunodeficiency virus promoter and is translated as an early gene; and (b) a second nucleotide sequence encoding a second reporter polypeptide that produces a second detectable signal that is distinguishable from the first detectable signal, where the second nucleotide sequence is operably linked to a non-immunodeficiency virus promoter. In some aspects, the first and second nucleotide sequences are both positioned between a shared 5? long terminal repeat (LTR) and a shared 3? LTR. Also provided are related methods.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: October 23, 2018
    Assignee: The J. David Gladstone Institutes
    Inventors: Eric M. Verdin, Vincenzo Calvanese
  • Patent number: 10087151
    Abstract: The present invention relates to compounds including but not limited to of any one of formulas Ia, Ib, IIa, IIb, IIIa, IIIb, and IV to VI, VIIa, VIIb, VIIIa, VIIIb and VIIIc as described herein and their tautomers and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: October 2, 2018
    Assignee: THE J. DAVID GLADSTONE INSTITUTES, A TESTIMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE
    Inventors: Andrey S. Tsvetkov, Steven M. Finkbeiner, Michael A. Pleiss, Robert Greenhouse
  • Patent number: 10004753
    Abstract: The present disclosure provides methods of reducing the level of acetylated Tau in a neuron or a glial cell in an individual, the methods involving administering to the individual a prodrug that is converted in the individual to salicylate. The present disclosure provides methods of treating a tauopathy in an individual, the methods involving administering to the individual a prodrug that is converted in the individual to salicylate.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: June 26, 2018
    Assignee: The J. David Gladstone Institutes
    Inventors: Li Gan, Xu Chen, Min Xie, Eric M. Verdin
  • Patent number: 10004751
    Abstract: The present disclosure provides methods of treating a flavivirus infection, and compositions for use in the methods.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: June 26, 2018
    Assignees: The J. David Gladstone Institutes, The Regents of the University of California
    Inventors: Melanie Ott, Andrew S. Kondratowicz, Nevan John Krogan, Priya Shirish Shah, Krystal Ann Fontaine
  • Patent number: 9982231
    Abstract: Compositions and methods are described herein for chemically inducing cells to change their differentiation state and become cardiac progenitor cells or cardiomyocytes.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: May 29, 2018
    Assignee: THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE
    Inventors: Nan Cao, Sheng Ding
  • Publication number: 20180125847
    Abstract: Methods for decreasing rod gene expression in a retina, methods for decreasing the protein products expressed by rod genes in a retina, methods for treating a disease or condition treatable by decreasing rod gene expression or their protein products in a retina, and methods for treating a retinal disease in a subject.
    Type: Application
    Filed: March 28, 2016
    Publication date: May 10, 2018
    Applicants: University of Washington, The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Glads
    Inventors: Thomas A. Reh, Paul Nakamura, Sheng Ding
  • Patent number: 9956260
    Abstract: Provided herein are compositions and methods for the treatment of a patient having an HIV-1 infection and/or AIDS. More specifically this invention provides treatment of an HIV-1 infection and/or AIDS using small molecule compounds, such as inhibitors for the activation and/or activity of caspase-1. Inhibitors for the activation and/or activity of caspase-1 also prevent the cell death of CD4 T-cells in a population of CD4 T-cells comprising HIV-1 infected CD4 T-cells and uninfected CD4 T-cells, In addition, caspase-1 inhibitors inhibit inflammation, and pyroptosis.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: May 1, 2018
    Assignee: The J. David Gladstone Institutes
    Inventors: Warner C. Greene, Gilad Doitsh, Orlando Zepeda, Nicole Galloway
  • Patent number: 9909104
    Abstract: Compositions and methods of producing mammalian cell populations that include a high proportion of definitive endoderm cells, posterior foregut-like progenitor cells, pancreatic progenitor cells and/or pancreatic beta cells are described herein. Such cell populations are useful for treatment of diabetes.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: March 6, 2018
    Assignee: The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
    Inventors: Sheng Ding, Ke Li, Saiyong Zhu
  • Patent number: 9885039
    Abstract: The present disclosure provides a method of increasing the functionality of a GABAergic interneuron in the hilus of the hippocampus of an individual having at least one apolipoprotein E4 (apoE4) allele. The method generally involves reducing tau levels in the interneuron.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: February 6, 2018
    Assignee: The J. David Gladstone Institutes
    Inventors: Yadong Huang, Yaisa Andrews-Zwilling
  • Patent number: 9835633
    Abstract: The present disclosure provides methods of identifying a candidate agent for treating an apoE-associated neurodegenerative disorder. The methods involve contacting a PCSK1 or a PCSK2 polypeptide with an apolipoprotein E polypeptide in the presence of a test agent.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: December 5, 2017
    Assignee: The J. David Gladstone Institutes
    Inventors: Yadong Huang, Qin Xu
  • Patent number: 9669112
    Abstract: The present invention provides non-human animal models of neuronal injury and/or cognitive dysfunction and methods of making and using such animal models. The animal models of the invention are particularly suited to assessing neurodegeneration in selected regions of interest in the CNS, and thus especially useful for testing the therapeutic efficacy of agents targeting neurodegeneration associated with aging, neurodegenerative diseases, autoimmunity and trauma (e.g., ischemia).
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: June 6, 2017
    Assignee: THE J. DAVID GLADSTONE INSTITUTES
    Inventors: Katerina Akassoglou, Jae Kyu Ryu